Off-market insider buying at MYM Nutraceuticals (MYM)

Off-market insider buying at MYM Nutraceuticals (C:MYM)

Rob Gietl, a Senior Officer and Director, acquired 60,000 Common Shares on a direct ownership basis at a price of $2.250 through a prospectus or prospectus exempt offering on February 26th, 2018. The insider also acquired 60,000 Warrants with an exercise price of $3.250 for 24 month. This represents a $135,000 investment into the company's shares and an account share holdings change of 10.4%.

On the same terms, Robin Linden, a Director, acquired 12,444 Common Shares and 12,444 Warrants on a direct ownership basis. This represents a $27,999 investment into the company's shares and an account share holdings change of 13.0%.

Mark Forster, a Senior Officer, acquired 9,333 Common Shares and 9,333 Warrants on a direct ownership basis. This represents a $20,999 investment into the company's shares and an account share holdings change of 1.4%. Finally, Sheryl Elsdon, a Senior Officer, acquired 6,222 Common Shares and 6,222 Warrants on a direct ownership basis. This represents a $14,000 investment into the company's shares and an account share holdings change of 62.2%.

MYM Nutraceuticals Inc. is focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.